William Blair Initiates Coverage On MaxCyte with Outperform Rating

William Blair analyst Matt Larew initiates coverage on MaxCyte (NASDAQ:MXCT) with a Outperform rating.

byBenzinga Newsdesk

August 24, 2021

1 minute read

William Blair analyst Matt Larew initiates coverage on MaxCyte (NASDAQ:MXCT) with a Outperform rating.

Morgan Stanley Maintains Overweight on Coca-Cola, Raises Price Target to $70

By Benzinga Newsdesk

Today, 6:35 PM

Morgan Stanley analyst Dara Mohsenian maintains Coca-Cola (NYSE:KO) with a Overweight and raises the price target from $68 to $70.

EXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia

By Vandana Singh

Today, 6:35 PM

Alzamend Neuro Inc (NASDAQ: ALZN) has partnered with the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for its Phase 1/2A trial of ALZN002.

ALZN

Goldman Sachs Maintains Neutral on Delta Air Lines, Raises Price Target to $44

By Benzinga Newsdesk

Today, 6:35 PM

Goldman Sachs analyst Catherine O'Brien maintains Delta Air Lines (NYSE:DAL) with a Neutral and raises the price target from $39 to $44.

DAL

Global
News

Minim Continues Global Expansion with Launch of Intelligent Networking Products in Amazon India and Flipkart

By Benzinga Newsdesk

Today, 6:35 PM

Minim, Inc. (NASDAQ:MINM), the creator of intelligent networking products under the globally recognized Motorola brand, today announced the launch of its intelligent networking products in India. Consumers can now find

AMZN

William Blair Initiates Coverage On MaxCyte with Outperform Rating

Related Posts

Morgan Stanley Maintains Overweight on Coca-Cola, Raises Price Target to $70

EXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia

Goldman Sachs Maintains Neutral on Delta Air Lines, Raises Price Target to $44

Minim Continues Global Expansion with Launch of Intelligent Networking Products in Amazon India and Flipkart